|Year : 2019 | Volume
| Issue : 1 | Page : 42-44
Subconjunctival bevacizumab for recurrent conjunctival pyogenic granuloma
Nirupama Kasturi1, Tharini Senthamizh1, Hanuman Srinivas Bheemanathi2, K Ramesh Babu1
1 Department of Ophthalmology, Jawaharlal Postgraduate Medical Education and Research, Puducherry, India
2 Department of Pathology, Jawaharlal Postgraduate Medical Education and Research, Puducherry, India
|Date of Submission||03-Nov-2018|
|Date of Decision||23-Dec-2018|
|Date of Acceptance||01-Apr-2019|
|Date of Web Publication||14-May-2019|
Department of Ophthalmology, Jawaharlal Postgraduate Medical Education and Research, Puducherry - 605 006
Source of Support: None, Conflict of Interest: None
| Abstract|| |
A 45-year-old male presented with a pyogenic granuloma of the bulbar conjunctiva of the left eye following a stick injury. It was a benign friable, hyperplastic, vascular lesion comprised of inflammatory cells and lobular capillary proliferation. The differential diagnosis includes squamous papillomas, hemangiomas, suture granulomas, and ocular surface tumors, such as squamous cell carcinoma and amelanotic melanoma. Conventional treatment includes topical corticosteroids and surgical excision. Treatment of recurrent lesions with cryotherapy, electrocautery, topical antimetabolites, and plaque irradiation has been described. We present a case of recurrent pyogenic granuloma successfully treated with two subconjunctival bevacizumab injections. The patient developed three recurrences after excision at a peripheral hospital after which he was successfully treated with excision and adjuvant subconjunctival bevacizumab 2.5 mg/0.1 ml injection. This case highlights the novel use of bevacizumab for recurrent pyogenic granuloma.
Keywords: Bevacizumab, conjunctival mass, pyogenic granuloma
|How to cite this article:|
Kasturi N, Senthamizh T, Bheemanathi HS, Babu K R. Subconjunctival bevacizumab for recurrent conjunctival pyogenic granuloma. J Pharmacol Pharmacother 2019;10:42-4
|How to cite this URL:|
Kasturi N, Senthamizh T, Bheemanathi HS, Babu K R. Subconjunctival bevacizumab for recurrent conjunctival pyogenic granuloma. J Pharmacol Pharmacother [serial online] 2019 [cited 2019 Sep 15];10:42-4. Available from: http://www.jpharmacol.com/text.asp?2019/10/1/42/258145
| Introduction|| |
Conjunctival pyogenic granulomas develop after conjunctival injury from trauma or surgery for squint, chalazion or a pterygium. It is a benign friable, vascular lesion comprised of inflammatory cells and lobular capillary proliferation. Conventional treatment includes topical corticosteroids and surgical excision. Treatment of recurrent lesions with cryotherapy, electrocautery, topical antimetabolites and plaque irradiation had been described. We present a case of recurrent pyogenic granuloma successfully treated with subconjunctival Bevacizumab injection.
| Case Report|| |
A 45-year-old male presented with a nodular mass in the lateral aspect of the left eye for 6 months. He had an injury to the left eye with a stick following which he developed redness and gradually increasing mass in the left eye. The patient underwent excision of the mass at a peripheral hospital, thrice before presenting to us. On examination, his visual acuity was 6/6 in both eyes. Right eye examination was within normal limits. Left eye showed a 4 mm × 3 mm pedunculated mass in the temporal bulbar conjunctiva [Figure 1].
|Figure 1: Clinical photograph of the left eye showing a pedunculated vascular lesion in the bulbar conjunctiva|
Click here to view
The patient underwent surgical excision, and a histopathological assessment was reported as pyogenic granuloma [Figure 2].
|Figure 2: Histopathological examination (a) showing conjunctival tissue with underlying proliferating vascular channels and inflammatory cells (H and E, ×100) and (b) showing vessels lined by benign endothelial cells admixed with lymphocytes (H and E, ×400) in keeping with a pyogenic granuloma|
Click here to view
A differential diagnosis of squamous papilloma, hemangioma, and ocular surface neoplasia was considered. On follow-up 1 month after the excision, a small 1.5 mm recurrence was noted for which subconjunctival injection of bevacizumab (2.5 mg/0.1 ml) was given twice at an interval of 2 weeks. On review 1 year after the injection, the granuloma showed resolution, with a small pseudopterygium temporally [Figure 3].
|Figure 3: Follow-up picture at 6 months showing complete resolution of the granuloma with a small pseudopterygium temporally|
Click here to view
| Discussion|| |
Conjunctival pyogenic granulomas develop after conjunctival injury from trauma or surgery for squint, chalazion, or a pterygium. Lesions can occur on the bulbar or palpebral conjunctiva, both of which can cause foreign body sensation, hemolacria, and poor cosmesis. Clinically, lesion is usually painless but may be tender and appears as a polypoid, friable, purple-red, smooth-surfaced mass that bleeds easily.
The term “pyogenic granuloma” is a misnomer as it neither is infective nor demonstrates epithelioid or giant cells on histopathology. It is better termed as lobular capillary hemangioma. The exact etiology of conjunctival pyogenic granulomas remains unknown. The proliferation of capillaries and inflammatory cell infiltration occurs due to the release of cytokines, including vascular endothelial growth factor (VEGF), fibroblast growth factor, and proinflammatory factors. It is plausible that conjunctival pyogenic granuloma formation results from an angiogenic imbalance during wound healing.
On histopathology, the basic lesion is a lobulated cellular hemangioma with a fibromyxoid matrix, and each lobule of the hemangioma consists of a larger vessel, often with a muscular wall, surrounded by congeries of small capillaries and stromal edema. Mitotic activity in the endothelial cells and fibroblasts may be conspicuous. Most pyogenic granulomas are altered by secondary inflammatory changes. Both acute and chronic inflammatory cells (predominantly neutrophils, lymphocytes, and plasma cells) are scattered throughout the lesion, particularly in its superficial layers.
Treatment is individualized ranging from topical medications such as corticosteroids or beta-blockers such as timolol to surgical excision. Majority of the lesions demonstrate a rapid growth followed by stabilization or spontaneous involution and heal with a small focal scar. Recurrence rate is reported to be 3%. Recurrent pyogenic granulomas of the conjunctiva can be challenging to treat. Various techniques such as cryotherapy, electrocautery, topical antimetabolites, intralesional steroids, and plaque irradiation have been described., However, despite cryotherapy or cautery, the lesion may recur. Topical antimetabolites such as mitomycin C or thiotepa can cause severe side effects, such as dry eye, corneal melt, and punctual stenosis, and plaque irradiation can cause cataract or scleral necrosis. Intravitreal bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody, is proven to be useful in the treatment of retinal and choroidal neovascularization. Subconjunctival bevacizumab has been investigated and used successfully in the treatment of corneal neovascularization, conjunctival papilloma, pterygium, and glaucoma filtration surgeries.,,, Notably, no significant local or systemic complications were detected in these studies.
Currently, there are no reports on the use of bevacizumab as adjuvant therapy for recurrent pyogenic granuloma. Here, we report a case of a middle-aged patient who was treated successfully by excision with a subsequent subconjunctival injection of bevacizumab; this patient showed no recurrence for 1 year. We adopted bevacizumab as an adjuvant treatment of recurrent pyogenic granuloma because the pathogenesis of pyogenic granuloma indicates a hyperplastic, neovascular response to an angiogenic stimulus with an imbalance of promoters (VEGF, decorin, and transcription factors) and inhibitors. Although complications, such as gastrointestinal perforation, arterial thromboembolic events, proteinuria, and hypertension, are observed among patients treated with systemic doses of bevacizumab, our patient was a healthy young male and did not develop any side effects with significantly lower subconjunctival dosage.
| Conclusion|| |
Pyogenic granuloma of the conjunctiva recurs in 3% of the cases after simple excision. Subconjunctival bevacizumab is useful in the treatment of recurrent pyogenic granuloma of the conjunctiva without any local or systemic adverse effects.
Declaration of patient consent
The authors certify that they have obtained all appropriate patient consent forms. In the form, the patient has given his consent for his images and other clinical information to be reported in the journal. The patient understands that his name and initials will not be published and due efforts will be made to conceal identity, but anonymity cannot be guaranteed.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Ferry AP. Pyogenic granulomas of the eye and ocular adnexa: A study of 100 cases. Trans Am Ophthalmol Soc 1989;87:327-43.
Tan IJ, Turner AW. Pyogenic granuloma of the conjunctiva. N Engl J Med 2017;376:1667.
Gündüz K, Shields CL, Shields JA, Zhao DY. Plaque radiation therapy for recurrent conjunctival pyogenic granuloma. Arch Ophthalmol 1998;116:538-9.
Doctor PP, Bhat PV, Foster CS. Subconjunctival bevacizumab for corneal neovascularization. Cornea 2008;27:992-5.
Lee CY, Chen HC, Meir YJ, Ma DH, Wu WC. Subconjunctival injection of bevacizumab for recurrent conjunctival papilloma: A case report. Can J Ophthalmol 2017;52:e156-9.
Singh P, Sarkar L, Sethi HS, Gupta VS. A randomized controlled prospective study to assess the role of subconjunctival bevacizumab in primary pterygium surgery in Indian patients. Indian J Ophthalmol 2015;63:779-84.
] [Full text]
Choi JY, Choi J, Kim YD. Subconjunctival bevacizumab as an adjunct to trabeculectomy in eyes with refractory glaucoma: A case series. Korean J Ophthalmol 2010;24:47-52.
Giblin AV, Clover AJ, Athanassopoulos A, Budny PG. Pyogenic granuloma – The quest for optimum treatment: Audit of treatment of 408 cases. J Plast Reconstr Aesthet Surg 2007;60:1030-5.
[Figure 1], [Figure 2], [Figure 3]